Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL27766381 | 0.95 | PARP1 (0.55) | PARP1NPC1RAB9ANR4A2KDM4E | |
| Hydrogen Peroxide SCHEMBL8452315 | 0.94 | PARP1 (0.62) | PARP1NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL4370629 | 0.93 | PARP1 (0.64) | PARP1NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL1259 | 0.93 | PARP1 (0.64) | PARP1NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL29351761 | 0.93 | PARP1 (0.64) | PARP1NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL10664817 | 0.91 | PARP1 (0.58) | PARP1NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL11628321 | 0.91 | PARP1 (0.58) | PARP1NPC1RAB9AKDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL8503466 | 0.91 | PARP1 (0.62) | PARP1NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL11613703 | 0.91 | PARP1 (0.62) | PARP1NPC1RAB9AKDM4EKMT2A | |
| SCHEMBL11105533 | 0.91 | PARP1 (0.62) | PARP1NPC1RAB9AKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3129372-B1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECH LTD (GB) | 2020-12-16 | — | — | EP | disclosed |
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| EP-3129372-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | Cancer Research Technology Limited (GB) | 2017-02-15 | — | — | EP | disclosed |
| US-20160347756-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. | 2016-12-01 | — | — | US | disclosed |
| EP-3004111-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | Cephalon, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | WINDTREE THERAPEUTICS, INC. | 2015-10-01 | — | — | US | disclosed |
| WO-2015148597-A1 | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | IGNYTA, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| WO-2014193932-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414763-B2 | Azaquinazoline inhibitors of atypical protein kinase C | PRKCQ, PRKCA, PRKCZ | PARP1 1508/4885NPC1 2389/4885RAB9A 1084/4885 |
| US-20150274720-A1 | Azaquinazoline Inhibitors Of Atypical Protein Kinase C | PRKCQ, PRKCA, PRKCZ | PARP1 1508/4885NPC1 2389/4885RAB9A 1084/4885 |
| US-20160347756-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | ALK, ACVR1, AGTR1 | PARP1 1099/4885NPC1 2243/4885RAB9A 3379/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | PARP1 414/4885NPC1 3543/4885RAB9A 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.